FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinatan	$\Gamma$	20E 40
Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Haviland Kate  (Last) (First) (Middle)  C/O FULCRUM THERAPEUTICS, INC.							Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [ FULC ]      Date of Earliest Transaction (Month/Day/Year)     06/11/2020								elationship of Reporting eck all applicable)			10% Ov Other (s below)	vner
26 LANDSDOWNE STREET  (Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							Liı	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					action	2A. Deemed Execution Date,			3. Transa	ction	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			or 5. Amou Securitic Benefici Owned F Reporte Transac		int of es Forn (D) o (I) (Ir d) tion(s)		n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)
Table II - Derivati (e.g., p.									,			, or Ben ble sec			instr. 3 a	and 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, 1 (Year) if any (Month/Day/Year) 8			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)  Date Expirate Expirate Date		r) xpiration	Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)  Amount of Num or Num of Of Securities Underlying Derivative Securities Underlying Underl		Deri Sec (Ins	rice of ivative urity tr. 5)	tive derivative ty Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Stock Option (right to buy)	\$17.63	06/11/2020			A		9,285	(=)	(1)	$\top$	6/10/2030	Common Stock	9,285	\$	60.00	9,285		D	

## Explanation of Responses:

1. This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

## Remarks:

/s/ Peter Thomson, as attorneyin-fact for Kate Haviland

06/15/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.